Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476888 | 0.94 | LSS (0.33) | LSSALDH1A1EPHX2 | |
| SCHEMBL25593112 | 0.85 | TSHR (0.41) | LSSKDM4EALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL27045475 | 0.81 | ACHE (0.39) | ALDH1A1 | |
| SCHEMBL13612632 | 0.79 | ACHE (0.40) | ALDH1A1 | |
| SCHEMBL1678797 | 0.77 | — | — | |
| SCHEMBL23767402 | 0.75 | ADH1C (0.50) | LSSKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7433084 | 0.75 | ADH1C (0.41) | LSSKDM4ESMN1; SMN2 | |
| SCHEMBL1680185 | 0.75 | ADH1C (0.50) | LSSKDM4ESMN1; SMN2 | |
| SCHEMBL19476562 | 0.74 | LSS (0.33) | LSSALDH1A1EPHX2SMN1; SMN2SLC6A2 | |
| SCHEMBL1161184 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185525-B1 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2016-12-14 | — | — | EP | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | CYP3A5, ADH5, AVPR2 | LSS 1582/4885KDM4E 2297/4885ALDH1A1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.